Senior Vice President, Chief Medical Officer and Director of Research and Development
Director of Hematopathology Services
Medical Director (Nashville, Tennessee)
Medical Director (Fort Myers, Florida)
Medical Director, Pharma Services and Hematopathologist
Medical Director (Aliso Viejo, California) and Director of Pathology Services
Director of Lymphoma Services and Hematopathologist
Hematopathologist / Molecular Pathologist
Senior Hematopathologist and Medical Director,
Senior Pathologist and Director, Consultative Services
Hematopathologist and Surgical Pathologist
Neal S. Goldstein, MDSenior Pathologist
Paul Kirshman, MDStaff Pathologist
Takako Mitsuhashi MD, PhDDermatopathologist and Surgical Pathologist
Miriam Bloch, MDStaff Pathologist, Pharma Services
George Csathy, MDStaff Pathologist, Pharma Services
Steven G. Brodie, PhD, FACMGVice President of Operations
Antony Bakke, PhD, D(ABMLI)Director of Flow Cytometry
Vincent Funari, PhD, (CGMBS)Technical Director of Molecular & Director of Clinical Bioinformatics
Bob Gasparini, MS, CLSp(CG), CLDirConsultant
Michele Hibbard Kempik, PhD, FACMGDirector of Genetics
John R. McGill, PhD, FACMGGDirector of Cytogenetics (Fort Myers, Florida)
Guoxian Sun, MD, DABMG, FACMGDirector of Cytogenetics
Maya Thangavelu, PhDDirector of Cytogenetics and Technical Director of FISH
Dr. Agersborg joined NeoGenomics as a Hematopathologist in 2011. Prior to joining NeoGenomics, Dr. Agersborg worked as a Hematopathologist at Quest Diagnostics Nichols Institute. She completed her post-graduate medical training in Anatomic Pathology at the University of California, San Francisco, including fellowships in Surgical Pathology and Hematopathology. Beginning her educational career at Stanford University, Dr. Agersborg completed a co-terminal B.S. with Honors and M.S. in Biology. After graduating from Stanford University, Dr. Agersborg studied at the University of Virginia, where she earned a combined M.D. in Medicine and Ph.D. in Microbiology. Dr. Agersborg has written many publications, including peer reviewed and non-peer reviewed books, chapters, articles, and a multitude of abstracts.
Dr. Hii is a practicing pathologist and board certified in Anatomic and Clinical Pathology as well as Hematology. Prior to joining NeoGenomics, he
served as Senior Pathologist and Director, Consultative Services at Clarient Pathology Services and Assistant Medical Director at U.S. Labs in
Irvine, CA. He received his medical degree as well as residency training at Loma Linda University and went on to complete a surgical pathology
fellowship at the Los Angeles County-University of Southern California Medical Center and a fellowship in hematopathology at Cedars-Sinai
Medical Center in Los Angeles. Dr. Hii is the current California Tumor Tissue Registry Co-Director for Web and Multimedia Development. He is a
member of the College of American Pathologists, American Society for Clinical Pathology, and American Society of Hematology.
Dr. Agrawal is board certified in Anatomic and Clinical Pathology as well as in Hematopathology. She completed her residency in the Combined Anatomic and Clinical Pathology program at Loma Linda University Medical Center after which she went on to complete a Hematopathology Fellowship at the City of Hope National Medical Center with Dr. Lawrence Weiss. She specializes in flow cytometry, review of bone marrows, lymph nodes and other hematopathology consults, as well as fluorescence in-situ hybridization.
Dr. Kirshman currently serves as a Staff Pathologist at NeoGenomics, and served as a Staff Pathologist at Clarient Diagnostic Services, Inc. for six years prior to the NeoGenomics acquisition in 2015. Previously, Dr. Kirshman served as a Staff Pathologist at Urocor and US Labs, where his focus was on prostate pathology. Dr. Kirshman received his medical degree from the University of Montpellier, France; residency training at Westchester County Medical Center in Valhalla, NY; and fellowship training in molecular pathology under Dr. Mark Sobel at National Institutes of Health in Bethesda, MD.
Dr. O’Malley currently serves as an Adjunct Associated Professor at MD Anderson Cancer Center/University of Texas. Dr. O’Malley completed two
hematopathology fellowships, one at Duke University and the second at Carolinas Medical Center. Dr. O’Malley has authored numerous articles,
books and book chapters. He is the author of “Atlas of Splenic Pathology”, as well as a co-author of the AFIP Fascicle of Neoplastic Disorders of
Lymph Node and Spleen, and was the first author on the AFIP Fascicle on Non-Neoplastic Disorders of Lymph Node and Spleen. Recent publications
include chapters on lymphoma diagnosis in Dabbs’ Diagnostic Immunohistochemistry and several chapters in Knowles’ Hematopathology.
Dr. O’Malley teaches at a broad range of venues. In addition to teaching at medical schools and residencies (such as MD Anderson, UCLA, USC)
and state pathology societies (most recently Arizona), he is the director of a four-day ASCP course in hematopathology. He has been on several
national committees and is currently a member of the CAP Immunohistochemistry Committee, and Cancer Biomarker Reporting Panel on both
Myeloid disease and Lymphoma. Dr. O’Malley’s areas of diagnostic expertise include adult and pediatric bone marrow diseases, lymphomas,
cutaneous hematologic disorders, splenic pathology, immunohistochemistry, flow cytometry and molecular diagnostics.
Dr. Bloch is board certified in Anatomic Pathology, Clinical Pathology and Cytopathology. After graduating from the School of Medicine at University of Kansas, she completed her internship and residency training at the Hospital of the University of Pennsylvania and then served as Assistant Professor of Pathology at Temple University Medical School. Subsequently, Dr. Bloch served as Laboratory Medical Director at several hospitals and private laboratories. Her focus is on cytopathology, biopharmaceutical research, and development.
Dr. Chen is board certified in Anatomic and Clinical Pathology as well as Hematology with over 20 years experience in medical research. Dr. Chen came to Clarient Pathology Services after serving as Director of Hematopathology and Flow Cytometry, as well as Interim Medical Director, at US Labs. He completed his residency training in pathology at Temple University School of Medicine and received his PhD in Molecular and Cellular Pathology from the same institution. Dr. Chen has also served as Associate Director of the Molecular Diagnostic Division and Assistant Professor of Pathology at Thomas Jefferson University and as Assistant Professor of Pathology at the University of Maryland.
Dr. Wang is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology. Dr. Wang completed his fellowship training in Hematopathology at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, MA and his residency training at Berkshire Medical Center/University Massachusetts Medical School in Pittsfield, MA. Before his residency training, he served as junior faculty at Harvard Medical School and as an assistant research scientist at Beth Israel Deaconess Medical Center in Boston, MA. He has more than 50 publications and presentations in scientific journals and at national/international scientific meetings, and his research focus is hematopoiesis and endothelial cell biology.
Dr. Chizhevsky completed his residency in the Combined Anatomic and Clinical Pathology program at Saint Barnabas Medical Center in
New Jersey where he served as Chief Resident. Dr. Chizhevsky went on to complete a fellowship in Hematopathology at City of Hope National
Medical Center with Dr. Lawrence Weiss. He has authored many publications in peer-reviewed medical journals. Dr. Chizhevsky’s diagnostic
interests lie in flow cytometry, lymph node pathology, adult and pediatric bone marrow pathology, immunohistochemistry, immunotherapy and
molecular diagnostics of both solid tumors and hematolymphoid neoplasms. He is a member of the College of American Pathologists, American
Society for Clinical Pathology and International Clinical Cytometry Society. Dr. Chizhevsky holds certifications in HER2 DUAL ISH Interpretation,
PD-L1 (SP142; Atezolizumab) Urothelial Carcinoma Interpretation, PD-L1 (22C3; Keytruda®) NSCLC Interpretation, PD-L1 (28.8; Opdivo®)
NSCLC Interpretation, and PD-L1 (28.8; Opdivo®) Melanoma Interpretation, as well as a Black Belt in Six Sigma.
Dr. Csathy has more than 20 years of experience in a variety of pathology practice settings. For the past several years, he worked with Clarient Diagnostic Services and its biopharmaceutical services group, and shared responsibility for Clarient’s cytopathology consult service. Prior to that, he focused on genitourinary pathology and solid tumor prognostic and predictive biomarkers while at U.S. Labs in Irvine, CA. He also worked for nearly a decade in the VA Greater Los Angeles Healthcare System, where his duties included surgical pathology and cytopathology, as well as overseeing the training of pathology residents. Dr. Csathy is a graduate of the University of Minnesota Medical School. He completed his pathology residency training at Cedars-Sinai Medical Center in Los Angeles, CA and is board certified in Anatomic and Clinical Pathology.
Dr. Zhao is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology, with over 29 years of professional experience. Dr. Zhao previously served as a staff pathologist at Cottage Hospital, Santa Barbara, CA and as a clinical instructor in the Department of Pathology, University of California, Irvine.
Dr. Goldstein completed his residency at UCLA and surgical pathology fellowship at Barnes Hospital/Washington University. He was a staff anatomic pathologist and director of immunohistochemistry laboratory at William Beaumont Hospital in Royal Oak, MI for 14 years and director of the anatomic molecular laboratory for seven years. He has published 130 peer-reviewed articles and five book chapters. He has taught numerous courses at the ASCP, USCAP, and CAP and served on numerous consensus conferences over his 21 years of practice. He was part of the Gynecology Oncology Group Pathology committee for 10 years and USCAP education committee for four years. He has given talks throughout the United States at many state and city pathology societies and throughout the world. Dr. Goldstein’s primary diagnostic interests lie in the areas of breast, gastrointestinal, gynecologic, liver, and molecular pathology and immunohistochemistry.
Dr. Mixon is the Medical Director for the NeoGenomics Tennessee laboratory, and serves as the Medical Director of LabPlus within St. Thomas Health System and of the medical laboratories at St. Thomas Midtown and St. Thomas West hospitals in Nashville, TN. Dr. Mixon received his medical degree from the University of South Alabama, College of Medicine in Mobile, Alabama, where he developed his interest and skill in cytogenetics. He received his pathology residency training at Vanderbilt University Medical Center. He has been active in cytogenetics throughout his entire medical career, and has a special interest in cancer cytogenetics. He is board certified in Anatomic and Clinical Pathology by the American Board of Pathology.
Dr. Sun has held positions at Integrated Oncology Laboratories, Genzyme Genetics, and Impath. He served as a cytogenetics lab director for 12 years. Prior to that, he was an associate director of cytogenetics at Quest Diagnostics, San Juan Capistrano, CA. Dr. Sun earned his medical degree with a WHO fellowship in Hematology/Oncology at UCLA in 1987. He completed his genetics training from Alfigen - The Genetics Institute in Pasadena, CA. Dr. Sun is board certified in clinical cytogenetics. His main interest is cancer genetics, particularly in cytogenetic and genomic alterations of hematopoietic neoplasms. Dr. Sun has published over 40 scientific articles and abstracts.
Dr. Maya Thangavelu is Director of Cytogenetics and Technical Director of FISH in Aliso Viejo, CA. She has extensive experience in academic and commercial laboratory settings, working with both constitutional and acquired cancer-related abnormalities. Dr. Thangavelu obtained her Ph.D. in Cytogenetics from Memorial University and her master’s degree in Genetic Counseling from Sarah Lawrence College. Following her postdoctoral fellowship at the University of Chicago, she held directorship of the Cytogenetics Laboratory and a faculty position at Northwestern University. Dr. Thangavelu is certified by the American Board of Medical Genetics in Clinical Cytogenetics, and is a fellow of the American College of Medical Genetics. She holds Cytogenetic Director licenses in California, Florida, and New York. Dr. Thangavelu is an approved CAP inspector.
Dr. Boisot is a practicing pathologist, and is affiliated with several hospitals in the San Diego area. Dr. Boisot received her medical degree and completed her residency in Anatomic and Clinical Pathology from the University of California, San Diego School of Medicine. She completed her transitional internship at Loma Linda University. Dr. Boisot completed her fellowship in hematopathology at Scripps Clinic – Scripps Green Hospital. Dr. Boisot is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology.
Dr. McGill serves as the Director of Cytogenetics at NeoGenomics Laboratories at Fort Myers, Florida.
Dr. McGill has extensive experience in cancer genetics as an NIH-funded scientist, academician and practitioner of cancer cytogenetics and FISH. Prior to his career in diagnostic laboratories, he was Chief, Division of Molecular Genetics at the Cancer Therapy & Research Center in San Antonio, Texas where he also held an academic appointment as Associate Professor, in the Department of Cellular & Structural Biology at The University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Dr. McGill received his Ph.D. in Biomedical Sciences from The University of Texas Health Science Center at San Antonio, in San Antonio, Texas. He completed fellowships in the molecular biology of aging at the University of Arkansas for Medical Sciences in Little Rock, Arkansas and in medical genetics at The University of Texas Health Science Center at San Antonio, San Antonio, Texas. He is a founding fellow of the American College of Medical Genetics and is board certified in Clinical Cytogenetics by the American Board of Medical Genetics and Genomics. Dr. McGill holds Directors Licenses for the States of Florida, California, and New York.
Dr. Padurean joined NeoGenomics as the Medical Director of the Fort Myers, Florida laboratory in 2016. Prior to joining NeoGenomics, Dr. Padurean served as a Hematopathologist at AmeriPath Milwaukee. Dr. Padurean received his medical degree from Institutul de Medicina in Timisoara, Romania. He conducted medical research in the field of cardiovascular biology at Massachusetts General Hospital/Harvard Medical School and Mount Sinai Medical Center, New York. Subsequently, he completed his pathology residency at Regions Hospital in St. Paul, Minnesota and hematopathology fellowship training at the University of Minnesota. Dr. Padurean has served with distinction in numerous positions of importance in the clinical and academic service arenas, including Assistant Professor at University of Minnesota Medical School in Minneapolis, Minnesota; Staff Pathologist at VA Medical Center in Minneapolis, Minnesota; and Staff Pathologist/Hematopathologist and Director of Hematology Laboratories of Wheaton Franciscan Healthcare in Milwaukee, Wisconsin. Dr. Padurean is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology by the American Board of Pathology. He earned an MBA in Healthcare Administration from the Quinlan School of Business at Loyola University Chicago.
Dr. Brodie is the President of the Pharma Services division at NeoGenomics. Previously he served as the company’s Chief Scientific Officer and Director of BioPharma Operations, and Director of Molecular and Cytogenetics. Prior to joining NeoGenomics in 2011, Dr. Brodie served as Senior Director of Cytogenetics, Assistant Director of Molecular Genetics, and Scientific Director of Maternal Serum Screening at Specialty Laboratories/Quest Diagnostics in Valencia, CA. Dr. Brodie trained pathology residents in genetic testing at both Loma Linda University Medical Center, where he served as the Affiliate Rotation Director, and University of Southern California, Keck School of Medicine, where he served as a Clinical Assistant Professor of Pathology. Prior to joining Quest Diagnostics, he held a variety of research and clinical positions at the National Institutes of Health, University of New Mexico School of Medicine, and UCLA David Geffen School of Medicine. Dr. Brodie received his genetics training at the UCLA/Cedar-Sinai Medical Center medical genetics training program in Los Angeles, CA. He received his Ph.D. from UNM School of Medicine and completed Clinical Genetics training in Cytogenetics and Molecular Genetics at UCLA. Dr. Brodie is Board Certified by the American Board of Medical Genetics in these specialties and holds Director licenses in Florida, California, and New York. Throughout his career, Dr. Brodie has held various research and clinical positions at the NIH, UNM and UCLA, and comes to us after directing high throughput testing in Cytogenetics, FISH, Molecular Genetics, and Oncology for Quest Diagnostics, Nichols Institute. He is also a CAP approved inspector.
Dr. Weiss received his BS summa cum laude and M.D. summa cum laude from the University of Maryland. He completed a residency in Anatomic Pathology at the Brigham and Women’s Hospital and a fellowship in surgical pathology at Stanford University Medical Center. He was previously an Assistant Professor of Pathology at Stanford, President of the Medical Staff, and Chairman of Pathology at the City of Hope. He is the author of over 500 papers and book chapters, as well as over a dozen books, including an AFIP Lymph Node Fascicle, Applied Immunohistochemistry, Lymph Nodes, and Knowles’ Hematopathology. His laboratory discovered the first molecular evidence linking the Epstein-Barr virus with Hodgkin Lymphoma. He has won numerous awards, including the Benjamin Castleman, Arthur Purdy Stout, and the United States-Canadian Academy of Pathology Young Investigator Award, and has delivered more than 250 national and international talks in pathology, including several named lectureships. He is on the editorial board of ten scientific journals, and is a past President of the Los Angeles Society of Pathologists. He has been listed in the book The Best Doctors in America since 1994. Dr. Weiss’s diagnostic interests lie in lymph node pathology, adrenal pathology, solid tumor pathology, and immunohistochemistry.
Dr. Chen is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology. Dr. Chen received his medical degree from Nanjing Medical University, his master’s degree from Peking University Health Science Center, and his Ph.D. from National Institute for Viral Disease Control and Prevention, China CDC. He was a postdoctoral fellow and then senior research associate at The Scripps Research Institute in La Jolla, CA. Dr. Chen completed his residency in Anatomic and Clinical Pathology at University of Arizona, Tucson, and completed his two-year fellowship in Hematopathology with subspecialties in lymphoma and lymph node pathology at NCI, NIH in Bethesda, MD, under Dr. Elaine S. Jaffe. Before joining NeoGenomics Laboratories as Director of Lymphoma Services in 2013, Dr. Chen was a hematopathologist and Associate Medical Director at Integrated Oncology (formerly U.S. Labs), LabCorp for over seven years.
Dr. Bakke received his Ph.D. in biochemistry from Caltech in Pasadena, CA. During a postdoctoral fellowship at the Scripps Clinic and Research Foundation in San Diego, CA he learned flow cytometry on an early BD FACS II. He joined the Rheumatology faculty at the University of Southern California in 1980 and completed research projects on SLE, scleroderma, leprosy and natural killer cells, while directing flow cytometry labs for both the Department of Medicine and the Cancer Center. In 1984, he joined the pathology faculty at Oregon Health & Science University Hospital in Portland, OR. During 27 years at OHSU, Dr. Bakke established both the Clinical Immunology/Flow Cytometry Laboratory in the Pathology Department and the Knight Cancer Institute Core Flow Cytometry Resource. He became a full professor at OHSU and completed research projects involving leukemia, lymphoma, PNH, immune thrombocytopenic purpura, rheumatoid arthritis, bacterial and viral infection. Dr. Bakke became a Diplomate of the American Board of Medical Laboratory Immunology in 2004 and served on the council for the International Clinical Cytometry Society from 2005 to 2010. Dr. Bakke was an early adopter of eight and ten-color flow cytometry and cell sorting for clinical specimens.
Dr. Albitar, M.D., is formally trained in clinical pathology, hematopathology, and genetics. During his professional and academic tenure, he has published over 300 publications including peer-reviewed papers, review articles and book chapters focused on molecular characterization and diagnosis of cancer. He has served as Chief Medical Officer and Director of Research and Development at NeoGenomics since 2012. Prior to NeoGenomics, Dr. Albitar served as the Medical Director of Hematopathology and Oncology and Chief of R&D for Hematopathology and Oncology, Quest Diagnostics. He has held academic positions at The University of Texas MD Anderson Cancer Center as Tenured Full Professor, Director of Leukemia and Director of Molecular Laboratory in the Departments of Laboratory Medicine/Pathology.
Dr. Wilfredo Blasini is board certified in Anatomic Pathology, Clinical Pathology and Hematopathology by the American Board of Pathology. He received his medical degree from University of Puerto Rico School of Medicine in San Juan, Puerto Rico. Subsequently, he completed a residency in Anatomic and Clinical Pathology and a fellowship in Hematopathology at Jackson Memorial Hospital-University of Miami Miller School of Medicine in Miami, Florida. Prior to joining NeoGenomics Laboratories, he worked as an Associate Hematopathologist at Coral Gables Hospital and Palmetto General Hospital in Miami, Florida and at Florida Cancer Specialists in Fort Myers, Florida. Dr. Blasini has authored several papers in pathology peer-review journals and presented at several national pathology conferences. He is a fellow of the College of American Pathologists.
Prior to joining NeoGenomics, Dr. Jegalian was a staff physician at the Cleveland Clinic, where she was responsible for a high volume of diverse hematopathology cases and teaching trainees. She worked closely with world-renowned lymphoma pathologist Dr. Elaine S. Jaffe during a hematopathology fellowship at the National Institutes of Health. Dr. Jegalian completed her undergraduate degree, medical degree, and Ph.D. in Molecular Biology (Medical Scientist Training Program), and her four-year pathology residency at University of California, Los Angeles. She is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology, and has written several well-cited publications.
Dr. Janatpour brings more than 20 years of pathology experience to NeoGenomics, most recently in a private laboratory where she was Director of Medical Affairs and Director of Pathologist Research. Dr. Janatpour completed her pathology resident training and Hematopathology fellowship at University of California, Davis Medical Center. She also holds a master’s degree in Clinical Research and she has an extensive background in hematopathology research.
Dr. Jiang is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology. She specialized in Hematology and Oncology in China and Germany. Dr. Jiang completed her residency in pathology at the University of Oklahoma Health Sciences Center and the George Washington University Medical Center. She also completed a fellowship in hematopathology at Scripps Clinic in La Jolla, California. Dr. Jiang has extensive experience in hematopathology and vital skills in surgical pathology and served as the medical director at Tustin Center of Integrated Oncology/ Labcorp, Inc.
Dr. Taylor brings her talent to NeoGenomics after several years as a hematopathologist at a private laboratory in California. Dr. Taylor has a specific interest in quality control and quality assurance. Dr. Taylor completed her pathology resident training at University of South Alabama Medical Center, and her hematopathology fellowship at The Methodist Hospital in Houston, TX.
Dr. Yang shares more than 25 years of experience in medical research and clinical service with subspecialties in Hematology, Anatomic Pathology and Clinical Pathology. Formerly an Assistant Professor of Pathology at the Medical College of Wisconsin and University of Florida, Dr. Yang received his resident training at Albany Medical Center in New York and a Fellowship of Hematopathology from the City of Hope National Medical Center in Duarte, California.
Dr. Mitsuhashi is board certified in Anatomic Pathology, Clinical Pathology, and Dermatopathology. Dr. Mitsuhashi received her medical degree from Tokyo Women’s Medical College in Japan, and her Ph.D. from Gunma University, School of Medicine in Maebashi, Japan. She was a post-doctoral fellow at Cardiovascular Research Institute in University of California, San Francisco. Dr. Mitsuhashi completed her residency in University of California, Irvine, and completed her fellowship in Dermatopathology at University of California, Irvine, under Dr. Ronald Barr. She was a clinical instructor in Department of Pathology, University of California Irvine, during 2003 to 2004. Prior to joining NeoGenomics, Dr. Mitsuhashi served as the Associate Medical Director at Integrated Oncology (formerly U.S. Labs) for 11 years.
Dr. Unger has been a renal pathologist at PathLogic in West Sacramento, California since 2002. She earned her medical degree from Wake Forest University in Winston-Salem, North Carolina, and completed her residency in Anatomic and Clinical Pathology at the University of California, Davis, where she also was Chief Resident. She then completed a fellowship in Hematopathology at the University of California, Davis, followed by a renal pathology fellowship at PathLogic. Dr. Unger is board certified in Anatomic and Clinical Pathology and holds a subspecialty certification in Hematopathology from the American Board of Pathology.
Dr. Hibbard was the Director of Genetics at Clarient Diagnostic Services, Inc. for eight years prior to the NeoGenomics acquisition. Previously, she spent six years as Director of Genetics at Irvine-based U.S. Labs and a year at Impath labs in New York. She has been responsible for the launch and direction of the operations of the cytogenetics programs at each of these laboratories and the technical operations of the cytogenetic, FISH, and molecular genetic laboratories. Dr. Hibbard completed her clinical genetics training at Harvard Medical School. She completed her post-doctoral research in the Department of Pathology at Brigham and Women’s Hospital and her thesis research in the Department of Microbiology and Molecular Genetics at the University of California, Irvine. She is board certified by the American Board of Medical Genetics in Clinical Molecular Genetics and Clinical Cytogenetics, and holds California licenses as a Clinical Molecular Genetic Molecular Biologist and Clinical Cytogeneticist. She is a fellow in the American College of Medical Genetics and also holds her New York COQ in Cytogenetics, Oncology, and Molecular Tumor Markers.
Dr. Qin is a board certified Clinical Cytogeneticist with over 26 years of experience in Clinical Cytogenetics. Previously, Dr. Qin served as Laboratory Director at Genzyme Genetics, California. After earning her medical degree, Dr. Qin completed a Fellowship at Washington University and an additional year at Yale University in Human Genetics. Subsequently, she received her fellowship training in Clinical Cytogenetics at Georgetown University. Previously, Dr. Qin served as a voluntary faculty member at the University of California, Irvine. Dr. Qin is certified by the New York State Department of Health, by the California Department of Public Health, and is a Fellow of American College of Medical Genetics.
Mr. Gasparini currently serves as a Consultant at NeoGenomics. Previously, he served as Chief Science Officer and on the Board of Directors. He also held the position of President from January 2005 through May 2011. Prior to joining NeoGenomics, Mr. Gasparini was Director of the Genetics Division for US Labs, and prior to that was the Molecular Marketing Manager for Ventana Medical Systems. Prior to Ventana, Mr. Gasparini was the Assistant Director of the Cytogenetics Laboratory for the Prenatal Diagnostic Center, an affiliate of Mass General Hospital. While at the Prenatal Diagnostic Center, Mr. Gasparini was also an Adjunct Professor at Harvard University. Mr. Gasparini is a licensed Clinical Laboratory Director and an accomplished author in the field of Cytogenetics and Fluorescence In-Situ Hybridization (FISH) testing. He received his BS in Biological Sciences from the University of Connecticut and his Master of Health Science from Quinnipiac University in Laboratory Administration.
Dr. Arain joined NeoGenomics in 2016. Dr. Arain is a board-certified pathologist with sub-specialty fellowship training in gastrointestinal pathology and cytopathology. Her professional experience includes roles as Medical Laboratory Director and staff pathologist at Specialized Pathology Laboratories, Centennial Pathologists and Heartland Clinic. Dr. Arain completed training as a Cytopathology Fellow at the University of California, Irvine and as a GI/Liver Pathology Fellow at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Arain has spoken at several conferences and has been involved in several case presentations, research projects and publications.
Dr. Hummel joined NeoGenomics as a Hematopathologist / Molecular Pathologist in 2016. Previously, Dr. Hummel served as a Hematopathologist / Molecular Pathologist for Novartis/Genoptix from 2014 to 2016 and Clarient Diagnostic Services from 2012 to 2014. Dr. Hummel completed her Molecular and Genetic Pathology fellowship at University of Pittsburgh Medical Center under Dr. Jeffrey Kant and her Hematopathology fellowship and Pathology residency at University of Michigan. Dr. Hummel obtained her medical degree from Medical College of Wisconsin, her Masters of Public Health in Infectious Diseases and Immunity from University of California, Berkeley and her Bachelors of Science from University of Wisconsin, Madison. Dr. Hummel has contributed to several publications and abstracts in hematopathology and solid tumors. In addition, Dr. Hummel has served as a Certified Inspector for the College of American Pathologists (CAP).
Prior to joining NeoGenomics in 2016, Dr. Morgan served as the Medical Director of Flow Cytometry at Pathologists Bio-Medical/medfusion Laboratories in Texas. Prior to this position, Dr. Morgan was Medical Director of Hematopathology at AmeriPath North Texas from 2005 to 2010. From 1996 to 2005, Dr. Morgan occupied multiple positions at Texas Tech University Health Sciences Center, including Director of Hematopathology and Flow Cytometry, and Coordinator of the Pathology Residency Program. Dr. Morgan was a tenured Professor of Anatomic and Clinical Pathology at the time of leaving Texas Tech University. He obtained his medical degree from the University of Texas Southwestern Medical School in 1982. His residency in Anatomic and Clinical Pathology was at Presbyterian/St. Luke's Medical Center in Denver, Colorado. Dr. Morgan is a Fellow of the College of American Pathologists and the American Society for Clinical Pathology.
Dr. William joined NeoGenomics as Medical Director, Pharma Services and Hematopathologist in 2017. She previously served as a general pathologist for multiple laboratories and hospitals, including Quest Diagnostics Nichols Institute and Natividad Medical Center. In addition, Dr. William worked as a Hematopathology Consultant for DAKO/Agilent, and has extensive experience in clinical trials as a researcher for Northwestern University Feinberg School of Medicine. She completed her Hematopathology Fellowship and Anatomic and Clinical Pathology Residency at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. William obtained her medical degree from Ain Shams University and her PhD in Clinical Pathology, Immunology from Cairo University. In addition, Dr. William has spoken nationally and internationally, and has contributed toward several publications.
Dr. Funari's background is in medical genomics and genetics. He is formally trained in bioinformatics and genetics and licensed as a clinical molecular biology and genetics scientist. He comes to us as a previous Director of Genomics Core and Associate professor at UCLA Medical Center with over 45 peer reviewed co-authored publications in genomics such as Nature Immunology, JAMA, Science, Nature Genetics, AJHG, Genomics, etc. As faculty, he trained 4 medical genetics and 2 pathology fellows, in addition to teaching graduate student classes at Cedars-Sinai on genomic profiling. His primary interests are bioinformatics and genomic approaches to precision medicine.
After undergraduate research at University of California, Los Angeles, he completed his doctorate in a clinical genetics lab developing novel algorithms to diagnose human metabolic disease using high throughput genomic technologies. Afterward he completed a post-doctorate at Stanford University in Department of Surgery in the Pat Brown and David Botstein group characterizing the first molecular profiles of Breast Cancer. The next 10+ years were as faculty at the Medical Genetics Institute at Cedars-Sinai Medical Center, Department of Pathology, and Department of Pediatrics working closely with Dr. David Rimoin and Stan Nelson to implement precision medicine in the clinic.
Currently, he is the Technical Director of the molecular lab leading our clinical bioinformatics, working with R&D, and IT as well as Sales and Marketing to further develop and promote our molecular and genetic tests offerings.